Company Overview and News

Teranga Gold - I Am Optimistic In The Medium Term

2018-03-07 seekingalpha
In the medium term Teranga share prices should be supported by the company's largest shareholder; since November 2017 this shareholder has purchased 2.05 million shares and is still buying.
Upvote Downvote

Teranga Gold: Get By With A Little Help From Gold Prices

2018-03-05 seekingalpha
Teranga Gold has an achievable organic growth pipeline supported by strong free cash flows from current operations.
Upvote Downvote

Top 20 Gold Mining Stocks For 2018

2018-01-02 seekingalpha
Above are my Top 20 gold mining stocks for 2018. All of these companies have large resources and are highly undervalued based on their cash flow potential at higher gold prices. They are on this list primarily because of their upside potential. These are either producers or development stocks, although there is one optionality play (Goldmining Inc).
Upvote Downvote

Teranga Gold Cornerstone Investor To Buy More Shares

2017-11-21 seekingalpha
On 17 November 2017, West Africa-focused gold miner Teranga Gold ( OTCPK:TGCDF) announced that its cornerstone investor David Mimran intends to acquire up to 5% of the its shares over the next twelve months. This will not result in shareholder dilution. Also, the cap on his position in Teranga has been lifted from 19.9% to 29.9%. Mimran currently holds a 19.8% stake in Teranga.
Upvote Downvote

Teranga Is Aiming To Become A Mid-Tier Gold Producer But The Market Isn't Buying It

2017-11-20 seekingalpha
In two separate announcements last week, the company delivered great drill results at its 'Golden Hill' project in Burkina Faso.
Upvote Downvote

Teranga Gold Corp's (TGCDF) CEO Richard Young on Q3 2017 Results - Earnings Call Transcript

2017-11-04 seekingalpha
Teranga Gold Corp CDA (OTCPK:TGCDF) Q3 2017 Results Earnings Conference Call November 2, 2017 8:30 AM ET
Upvote Downvote

Admission to AIM and First Day of Dealings

2017-08-10 londonstockexchange
Upvote Downvote

Teranga Gold's (TGCDF) CEO Richard Young on Q2 2017 Results - Earnings Call Transcript

2017-07-29 seekingalpha
Teranga Gold Corp CDA (OTCPK:TGCDF) Q2 2017 Earnings Conference Call July 28, 2017 8:30 AM ET
Upvote Downvote

Is Teranga Gold Still A Solid Growth Stock?

2017-07-25 seekingalpha
Teranga Gold's stock has underperformed this year; my previous #10 gold stock pick is down nearly 30% YTD.
Upvote Downvote

Teranga Gold Achieves Record Q2 Production and Confirms Banfora Feasibility Study Results Expected in August

2017-07-13 marketwired
- Board approves an additional $10 million towards construction readiness activities at Banfora gold project in advance of major construction decision
Upvote Downvote

Sarama Resources Increases Exploration Interests in the Hounde Belt, Burkina Faso

2017-05-16 marketwired
VANCOUVER, BC--(Marketwired - May 16, 2017) - Sarama Resources Ltd. ("Sarama" or the "Company") (TSX VENTURE: SWA) is pleased to advise that it has agreed to acquire a 100% interest in the Botoro exploration property ("Botoro" or the "Property") in south-west Burkina Faso. Botoro complements Sarama's mineral property interests in the highly prospective southern Houndé Belt and increases the size of its 100%-owned4 ThreeBee Project to approximately 660km².
Upvote Downvote

Teranga Gold Announces Effective Date of 1 for 5 Share Consolidation

2017-05-03 marketwired
TORONTO, ONTARIO--(Marketwired - May 3, 2017) - Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ)(ASX:TGZ) is pleased to announce that the 1 for 5 consolidation of its common shares ("Common Shares") that was approved at the recent annual and special meeting of shareholders of the Company ("Shareholders"), will be effective on May 5, 2017. The Common Shares are expected to commence trading on the Toronto Stock Exchange on a post-consolidation basis on May 8, 2017.
Upvote Downvote

Teranga Gold Announces Voting Results From Annual and Special Meeting of Shareholders

2017-05-02 marketwired
TORONTO, ONTARIO--(Marketwired - May 2, 2017) - Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ)(ASX:TGZ) announced that all nominee directors listed in the Management Proxy Circular dated April 3, 2017 were elected as directors of the Company at its Annual and Special Meeting of Shareholders (the "Meeting") held earlier today in Toronto, Ontario. At this Meeting, 311,621,281 shares were voted, representing 58.
Upvote Downvote

Teranga Gold Annual and Special Meeting of Shareholders Scheduled for May 2, 2017

2017-04-28 marketwired
TORONTO, ONTARIO--(Marketwired - April 28, 2017) - Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ)(ASX:TGZ) announced today that it will host Teranga's Annual and Special Meeting of Shareholders on Tuesday, May 2, 2017 at 9:30 a.m. ET at the TMX Broadcast Centre in The Exchange Tower located at 130 King Street West, Toronto, Ontario.
Upvote Downvote

Teranga Gold Reports Strong Q1 2017 Production and Financial Results

2017-04-27 marketwired
Organic growth prospects advancing with the completion of the Banfora feasibility study on track for mid-year and two gold discoveries at Golden Hill
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

12h - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...